drugset / Trial / NCT02562612

Study of SM-88 in Advanced Cancers

NCT02562612

Phase 1/2 Withdrawn Tyme, Inc
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to collect response and pharmacokinetic data on the oral administration of a cocktail combination of 4 drugs being developed for the indication of metastatic breast cancer.

Timeline

Start
2022-10
Primary completion
2023-10
Completion
2023-10

Drugs

EvaluationDrugModalityDoseRoute
Subject SM-88 Unknown Oral

Indications